BRAIN ACCESS
LIVE

Serial Number

90042690

Owner

Braizon Therapeutics, Inc.

Attorney

M. Scott Alprin

Filing Date

Jul 8, 2020

Add to watchlist:

No watchlists yet
View on USPTO

BRAIN ACCESS Trademark

Serial Number: 90042690 • Registration: 6945464

BRAIN ACCESS is a trademark filed by Braizon Therapeutics, Inc. on July 8, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Braizon Therapeutics, Inc. (3 trademarks)

Bunkyo-ku, Tokyo 113-0033 , JP

Entity Type: 99

Trademark Details

Filing Date

July 8, 2020

Registration Date

January 10, 2023

Published for Opposition

October 25, 2022

Goods & Services

Custom manufacture of pharmaceuticals; processing of medicinal materials; Custom manufacture of chemicals, except for chemicals for in vitro diagnostic use

Pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the prevention of central nervous system diseases; pharmaceutical preparations for the prevention of central nervous system disorders; pharmaceutical preparations for the treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the brain for the treatment of central nervous system diseases; pharmaceutical preparations for the brain for the treatment of central nervous system disorders; pharmaceutical preparations for the brain for the prevention of central nervous system diseases; pharmaceutical preparations for the brain for the prevention of central nervous system disorders; pharmaceutical preparations for the brain for treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for the brain for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of central nervous system diseases; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of central nervous system disorders; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of central nervous system diseases; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of central nervous system disorders; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the treatment of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; pharmaceutical preparations for drug delivery systems which deliver medicament for the brain into the brain for the prevention of dementia, Alzheimer's disease, schizophrenia, depressive disorder, depression, and autism spectrum disorder; dietary supplements for humans; dietary supplements for animals; in vivo diagnostic agents for medical purposes specifically for analyzing the central nervous system; radio-isotope markers for therapeutic or in vivo diagnostic use

Chemicals, namely, chemicals for in vivo industrial use for analyzing the central nervous system; chemicals used in industry for in vivo analysis of the central nervous system

Testing, inspection or research of pharmaceuticals, chemicals or cosmetics, except for chemicals for in vitro diagnostic use; testing the functionality of machines, except for machines for in vitro diagnostic use; research on machines, except for machines for in vitro diagnostic use

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 10, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 10, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 25, 2022 NPUB
PUBLISHED FOR OPPOSITION
Oct 25, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 5, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 22, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 22, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 22, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 22, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 22, 2022 CNEA
ASSIGNED TO EXAMINER
Sep 21, 2022 DOCK
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Sep 21, 2022 ZZZX
ASSIGNED TO EXAMINER
Sep 21, 2022 DOCK
WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST
Sep 21, 2022 PBMR
CASE RETURNED TO EXAMINATION
Sep 20, 2022 OTHE
NOTICE OF ALLOWANCE CANCELLED
Sep 20, 2022 IUCN
ASSIGNED TO EXAMINER
Sep 19, 2022 DOCK
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Sep 19, 2022 PCBG
ASSIGNED TO PETITION STAFF
Sep 15, 2022 APET
TEAS PETITION TO AMEND BASIS RECEIVED
Aug 22, 2022 TPAD
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 12, 2022 NOAM
TTAB RELEASE CASE TO TRADEMARKS
May 27, 2022 TMBN
OPPOSITION TERMINATED NO. 999999
May 27, 2022 OP.T
OPPOSITION DISMISSED NO. 999999
May 27, 2022 OP.D
OPPOSITION INSTITUTED NO. 999999
Nov 22, 2021 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Jun 16, 2021 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 25, 2021 NPUB
PUBLISHED FOR OPPOSITION
May 25, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 5, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 19, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 19, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 19, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 19, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 17, 2020 GNRN
NON-FINAL ACTION E-MAILED
Oct 17, 2020 GNRT
NON-FINAL ACTION WRITTEN
Oct 17, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 15, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 5, 2020 NWOS
NEW APPLICATION ENTERED
Jul 11, 2020 NWAP